CAM
ARCT icon

Cresset Asset Management’s Arcturus Therapeutics ARCT Stock Holding History

Cresset Asset Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,511
Closed -$195K – 1719
2024
Q4 		$195K Sell
11,511
-2,198
-16% -$41.4K ﹤0.01% 1572
2024
Q3 		$318K Sell
13,709
-2,435
-15% -$52.1K ﹤0.01% 1774
2024
Q2 		$393K Buy
+16,144
New +$490K ﹤0.01% 1570
2021
Q4 		– Sell
-4,412
Closed -$210K – 1132
2021
Q3 		$210K Buy
+4,412
New +$198K ﹤0.01% 1006

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Cresset Asset Management's ARCT Position: Q1 2025 in Review

Cresset Asset Management sold out of Arcturus Therapeutics (ARCT) in Q1 2025, closing a stake of 11,511 shares — an estimated $195K sold.

Cresset Asset Management first reported a position in ARCT in Q3 2021 and held it in 4 quarters. The position peaked at $393K in Q2 2024. 145 funds tracked by Wall St. Rank hold ARCT as of Q1 2025.

  • Cresset Asset Management reported no remaining Arcturus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Cresset Asset Management sold 11,511 Arcturus Therapeutics shares in Q1 2025, an estimated $195K.
  • Cresset Asset Management first reported a position in Arcturus Therapeutics in Q3 2021 and held it in 4 quarters.
  • Cresset Asset Management's Arcturus Therapeutics position peaked at $393K in Q2 2024.
  • 145 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2025.

Based on Cresset Asset Management's 13F filing for Q1 2025, filed 13 May 2025.